Navigation Links
Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
Date:5/21/2009

FRAZER, Pa., May 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today the pricing of its concurrent public offerings of 5 million shares of common stock, at a price of $60 per share, and $435 million in aggregate principal amount of 2.50% convertible senior subordinated notes due 2014. Cephalon has also granted the underwriters a 30-day option, solely to cover over-allotments, to purchase up to an additional 750,000 shares of common stock, with respect to the common stock offering, and to purchase up to an additional $65 million in aggregate principal amount of the notes, with respect to the notes offering.

The notes will bear interest at a rate of 2.50% per year, payable on May 1 and November 1 of each year, commencing on November 1, 2009. The notes will mature on May 1, 2014. Holders may require the Company to repurchase all or a portion of their notes upon a fundamental change (as defined in the prospectus supplement relating to the notes) at a cash repurchase price equal to 100% of the principal amount plus accrued and unpaid interest. Cephalon may not redeem the notes prior to the maturity date.

The notes are convertible prior to maturity, subject to certain conditions, into cash and shares, if any, of the Company's common stock at an initial conversion price of $69.00 per share of common stock (equivalent to a conversion rate of approximately 14.4928 shares per $1,000 principal amount of notes). The notes will be subordinate to existing and future senior indebtedness, equal to existing and future senior subordinated indebtedness and senior in right of payment to existing and future subordinated indebtedness of Cephalon.

The aggregate net proceeds from the sale of shares of common stock and the notes being offered are expected to be approximately $709.5 million, after deducting the
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
2. Cephalons New Product Launches Pace Record 2008 Sales
3. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
4. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
5. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
6. Cephalon, Inc. to Webcast Analyst Day
7. Cephalon Reports Another Strong Quarter
8. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
9. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
10. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
11. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , NEW YORK, Nov. 25 Rep... report is available in its catalogue: ,, Braz...3 ,, http://www.reportlinker.com/p0165503/Bra...13.html ,, Brazil Bioethanol Market Analysis a...ort provides detailed analysis and forecasts of th...
(Date:11/24/2009)... The New York investment bank ...SX:NEU) has agreed an AU$6.7 mil convertible note ...or. The private placement was arranged by KTA Capi...sor. , New York (PRWEB) N...tment bank KTA Capital, LLC ("KTA Capital&quo...
(Date:11/24/2009)... Health care employment grew...the only one to show consistent growth during the ...pitals remain in trouble, and health systems are c...sonnel, instead of just administrators. , ...th care employment continued growing in October de...
(Date:11/24/2009)... , SEATTLE, Nov. 24 Blue Marbl...d the Odessa Public Development Authority (OPDA) w...e,s Community Economic Revitalization Board (CERB)...state,s first specialty biochemical biorefinery in... significantly speed the development of our bioref...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...n, Wis. The state will give $250,000 in tax cred... to help it build an 18,000-square-foot facility i... to Governor Jim Doyle,s office, the $2.4 million ...ts are part of Wisconsin,s Technology Zone Progra...for each of eight zones of the state. , ,Credits a...
..., Wis. Recent developments in Washington and Kor... cell community, putting more roadblocks in scient...l effort by South Korean scientists to create "pat...DNA of injured patients, President Bush has renewe...nding restrictions on stem-cell research in the Un...
...e Department of Commerce has qualified 10 more bus...which allows investors in small research and devel...y back. , ,Commerce can give out up to $3.5 millio...per year for at least 10 years. It,s up to the bus...ld just have to sign the paperwork. , ,Investors s...
Other Biology Technology:Wisconsin aims to keep up in changing stem-cell world 2Wisconsin aims to keep up in changing stem-cell world 3
(Date:11/26/2009)...lberg, 27 November 2009 What are the bare essenti...d to produce a cell that can survive on its own? C...d understand how an entire organism functions as a... scientists in a partnership between the European ... Germany, and the Centre de Regulacio Genmica (CRG...
(Date:11/25/2009)...a hormone produced in the stomach, may be used to ...arkinson,s disease, Yale School of Medicine resear...e of the Journal of Neuroscience . , Parkinson,...neurons in an area of the midbrain known as the su...production. Reduced production of dopamine in lat...
(Date:11/25/2009)...it Larisch, Head of the Cell Death Research Labora...ology, has been awarded the prestigious Johnson & ...loring the cause of brain cell damage in Parkinson...to scientists in support of innovation and excelle...lly conferred earlier this month at an event at th...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Hormone ghrelin can boost resistance to Parkinson's disease 2Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 1Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 2Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 3Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 4Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 5Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cance 58487 6Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 5076 1Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 5076 2Zeltiq Aesthetics Names Gordie Nye to Serve as New CEO 5076 3Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call 3B October 1 2009 at 4 3A30 p m Eastern 5072 1Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call 3B October 1 2009 at 4 3A30 p m Eastern 5072 2
...mon laboratory test that predicted poor outcome fr...t for head and neck cancers now has been found to ...or suppressor gene therapy - making it potentially...sed drug. , Researchers at Introgen Therapeutics, ...dvanced squamous cell carcinoma of the head and ne...
...ublic Library of Science (PLoS) announced today th...e first open access journal devoted to the world,s...al Diseases ( www.plosntds.org ) will focus on the...e every year in poor countries, including elephant...somiasis, and African sleeping sickness. The jour...
...e addicted to cocaine have an impaired ability to ...ptions in the brain,s reward and control circuits,...d neuropsychological tests conducted at the U.S. D...ry. , "Our findings provide the first evidence tha... rewards is modified in drug-addicted people, and ...
Other Biology News:Abnormal overexpression of p53 is a predictive molecular biomarker 2Public Library of Science to launch new, open access journal on neglected tropical diseases 2Public Library of Science to launch new, open access journal on neglected tropical diseases 3Altered perception of reward in human cocaine addiction 2Altered perception of reward in human cocaine addiction 3
...hase extraction through columns is a well-known se.... Typical applications are in DNA/RNA extraction i..., or compound purification in chemical or analytic...n the Genesis series instruments for smaller scale...
...is Tecan's pipetting software for life science app...the GENESIS WORKSTATION instruments including the ...ware enables the user the simple graphical configu...pts. With the powerful scripting language the most...
POLYCLONAL ANTIBODY PRODUCTION from Global Peptide Services, LLC.
...Genomics Solution is a comprehensive suite of adva... specifically designed to reliably extract biologi...nal genomic studies containing thousands of sample...ent and will analyze large data sets on a personal...
Biology Products: